# US 2022/0016270 A1 · Radiopaque monomers, polymers, microspheres, and methods related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016270 A1
- Document ID: US20220016270A1
- Status: Published application
- Kind: A1
- Application number: 17/385,735
- Filed: 2021-07-26
- Published: 2022-01-20
- Earliest claimed: 2015-01-12
- Assignees: Biosphere Medical, Inc.
- Applicants: Biosphere Medical, Inc.
- Inventors: Philippe Reb
- Web page: https://patentgrep.com/patent/US20220016270A1

## CPC

- C08F 220/585: {and containing other heteroatoms, e.g. 2-acrylamido-2-methylpropane sulfonic acid [AMPS]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/02: Inorganic compounds
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61K 49/0442: {Polymeric X-ray contrast-enhancing agent comprising a halogenated group}
- A61K 49/048: {Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer}
- A61K 49/126: {Linear polymers, e.g. dextran, inulin, PEG}
- A61K 49/1818: {particles, e.g. uncoated or non-functionalised microparticles or nanoparticles}
- A61K 49/1854: {the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol}
- C07C 231/08: from amides by reaction at nitrogen atoms of carboxamide groups
- C08F 220/58: containing oxygen in addition to the carbonamido oxygen {, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine}
- C08F 222/385: {Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide}
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of embolization, comprising:
injecting an embolic composition into a blood vessel of a patient, the composition comprising:
a polymer comprising a polymerized monomer having a structure according to Formula I:
wherein n is 0-12 and wherein R is either an oxygen-containing moiety or a nitrogen-containing moiety.

### Claim 22 (depends on 21)

The method of claim 21, wherein the monomer has a structure according to Formula Ia:
or a salt thereof.

### Claim 23 (depends on 21)

The method of claim 21, wherein the monomer has a structure according to Formula Ib:
or a salt thereof.

### Claim 24 (depends on 21)

The method of claim 21, wherein the polymer comprises an anionic functional group.

### Claim 25 (depends on 21)

The method of claim 21, wherein the polymer comprises a cationic functional group.

### Claim 26 (depends on 21)

The method of claim 21, wherein the polymer is non-resorbable within a body of a patient.

### Claim 27 (depends on 21)

The method of claim 21, wherein the polymer is radiopaque.

### Claim 28 (depends on 21)

The method of claim 21, wherein the composition comprises microspheres.

### Claim 29 (depends on 21)

The method of claim 21, wherein the composition further comprises at least one of a cross-linker, a gelatin, or a coloring agent.

### Claim 30 (depends on 21)

The method of claim 21, wherein the composition further comprises an additional radiopaque agent.

### Claim 31 (depends on 21)

The method of claim 21, wherein the composition further comprises a magnetic agent.

### Claim 32 (depends on 21)

The method of claim 21, further comprising:
detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.

### Claim 33

A method of embolization, comprising:
injecting an embolic composition into a blood vessel of a patient, the composition comprising:
a polymer comprising a polymerized monomer comprising a polymerizable group; a spacer; an anionic functional group; and an iodine;
wherein the polymer is radiopaque.

### Claim 34 (depends on 33)

The method of claim 33, wherein the polymerized monomer comprises a structure according to Formula I:
wherein n is 0-12 and wherein R is either an oxygen-containing moiety or a nitrogen-containing moiety.

### Claim 35 (depends on 33)

The method of claim 33, further comprising:
detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.

### Claim 36 (depends on 33)

The method of claim 33, wherein the polymer is non-resorbable within a body of the patient.

### Claim 37 (depends on 33)

The method of claim 33, wherein the composition comprises microspheres.

### Claim 38

A method of embolization, comprising:
injecting an embolic composition into a blood vessel of a patient, the composition comprising:
a polymer comprising a polymerized monomer comprising a polymerizable group; a spacer; an anionic functional group; and an iodine;
wherein the polymer is non-resorbable within a body of the patient,
wherein the polymer is radiopaque, and
detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.

### Claim 39 (depends on 38)

The method of claim 38, comprising:
detecting a location of the polymer more than about a week, or more than about a month after introduction of the polymer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the composition comprises microspheres.
